|
STAB1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.69619898524343E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.9253491830068E-12 |
| Normal-vs-Stage2 |
2.47839999999444E-05 |
| Normal-vs-Stage3 |
1.042250E-04 |
| Normal-vs-Stage4 |
3.796600E-03 |
| Stage1-vs-Stage2 |
6.057600E-01 |
| Stage1-vs-Stage3 |
4.389600E-02 |
| Stage1-vs-Stage4 |
4.339500E-02 |
| Stage2-vs-Stage3 |
7.527900E-02 |
| Stage2-vs-Stage4 |
5.328100E-02 |
| Stage3-vs-Stage4 |
6.510800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.59190011067767E-10 |
| Normal-vs-AfricanAmerican |
1.352200E-02 |
| Normal-vs-Asian |
3.73170000012024E-07 |
| Caucasian-vs-AfricanAmerican |
5.055800E-01 |
| Caucasian-vs-Asian |
2.063800E-01 |
| AfricanAmerican-vs-Asian |
1.375770E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.72329999954025E-09 |
| Normal-vs-Female |
1.34269995122338E-09 |
| Male-vs-Female |
8.868400E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.32330035818029E-10 |
| Normal-vs-Age(41-60Yrs) |
7.18210000361097E-08 |
| Normal-vs-Age(61-80Yrs) |
6.35879999999478E-05 |
| Normal-vs-Age(81-100Yrs) |
7.819500E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.782000E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.497560E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.812800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.088400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.076600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.025000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.987800E-02 |
| Classical-VS-Follicular |
7.101400E-01 |
| Classical-VS-Other |
5.692400E-01 |
| Classical-VS-Normal |
4.50450010625048E-10 |
| Tall-VS-Follicular |
1.232990E-01 |
| Tall-VS-Other |
7.862800E-01 |
| Tall-VS-Normal |
1.161960E-01 |
| Follicular-VS-Other |
5.508200E-01 |
| Follicular-VS-Normal |
1.70259999998645E-06 |
| Other-VS-Normal |
5.856000E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.74540398695444E-11 |
| Normal-vs-N1 |
1.429580E-04 |
| N0-vs-N1 |
2.683800E-01 |
|
|
